IPSC

NASDAQ open

Century Therapeutics

1.20 USD
▼-0.13-9.47%
盘后 1.51 0.00%
2026-11-20
市值
$211.56M
市盈率
—
EPS
-0.57
股息率
—
52 周区间
0.46 – 3.04
成交量
660.10K
Beta
1.77
目标价
4.75
52W 低 0.4652W 高 3.04
价格走势

公司简介

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoim...